This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Pilewskie M, Stemple M, Rosenfeld H, et al. Do LORIS trial eligibility criteria identify a ductal carcinoma in situ patient population at low risk of upgrade to invasive carcinoma. Ann Surg Oncol. 2016;23:3487–93.
Francis A, Thomas J, Fallowfield L, et al. Addressing overtreatment of screen detected DCIS; the LORIS trial. Eur J Cancer. 2015;51:2296–303.
Wells WA, Carney PA, Eliasson MS, Grove MR, Tosteson ANA. Pathologists’ agreement with experts and reproducibility of breast ductal carcinoma in situ classification schemes. Am J Surg Pathol. 2000;24:651–9.
Schuh F, Biazus JV, Resetkova E, Benfica CZ, Edelweiss MIA. Reproducibility of three classification systems of ductal carcinoma in situ of the breast using a web-based survey. Pathol Res Pract. 2010;206:705–11.
Douglas-Jones A, Morgan JM, Appleton MAC, et al. Consistency in the observation of features used to classify duct carcinoma in situ (DCIS) of the breast. J Clin Pathol. 2000;53:596–602.
Kim J, Han W, Lee JW, et al. Factors associated with upstaging from ductal carcinoma in situ following core needle biopsy to invasive cancer in subsequent surgical excision. Breast. 2012;21:641–5.
About this article
Cite this article
Rea, D., Francis, A., Wallis, M. et al. Confusion Over Differences in Registration and Randomization Criteria for the LORIS (Low-Risk DCIS) Trial. Ann Surg Oncol 24, 566–567 (2017). https://doi.org/10.1245/s10434-017-6174-y